Get the Stockscreener App
2.30
6.12%
-0.15
After Hours:
2.30
Nucana Plc Adr stock is traded at $2.30, with a volume of 464.52K.
It is down -6.12% in the last 24 hours and down -37.16% over the past month.
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
See More
Previous Close:
$2.45
Open:
$2.47
24h Volume:
464.52K
Relative Volume:
0.35
Market Cap:
$5.17M
Revenue:
-
Net Income/Loss:
$-33.44M
P/E Ratio:
-3.0488
EPS:
-0.7544
Net Cash Flow:
$-28.30M
1W Performance:
-28.79%
1M Performance:
-37.16%
6M Performance:
-64.62%
1Y Performance:
-84.92%
1-Day Range:
$2.25
$2.50
1-Week Range:
$2.25
$3.66
52-Week Range:
$2.25
$20.26
Nucana Plc Adr Stock (NCNA) Company Profile
Nucana Plc Adr Stock (NCNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-03-22 | Downgrade | Cowen | Outperform → Market Perform |
| Oct-22-20 | Initiated | Truist | Buy |
| Jul-24-20 | Initiated | Oppenheimer | Outperform |
| Aug-19-19 | Initiated | H.C. Wainwright | Buy |
| Oct-19-18 | Initiated | Piper Jaffray | Overweight |
| Oct-23-17 | Initiated | Citigroup | Buy |
| Oct-23-17 | Initiated | Jefferies | Buy |
| Oct-23-17 | Initiated | William Blair | Outperform |
View All
Nucana Plc Adr Stock (NCNA) Latest News
Trading Day Triumph: NuCana plc ADR (NCNA) Ends at 2.45, a -10.91 Surge/Plunge - The Dwinnex
Get in on NuCana plc ADR’s (NCNA) buy-in window today! - SETE News
NuCana plc ADR Inc. (NCNA) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
NCNA’s price-to-sales ratio: Is it a good investment opportunity? - US Post News
Market Watch: NuCana plc ADR (NCNA)’s Noteworthy Drop, Closing at 3.05 - The Dwinnex
NuCana secures new US patent for cancer treatment NUC-7738 - Investing.com
Daily Market Movement: NuCana plc ADR (NCNA) Sees a -7.03 Decrease, Closing at 3.44 - The Dwinnex
William Blair downgrades NuCana plc ADR (NCNA) rating to a Mkt perform - Knox Daily
There is no doubt that NuCana plc ADR (NCNA) ticks all the boxes. - SETE News
Wolfspeed Inc [WOLF] Investment Appeal on the Rise - Knox Daily
Labcorp Holdings Inc. (LH) may enjoy gains as insiders got busy in the recent days - Knox Daily
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study - Yahoo Finance
NCNA’s Financial Health: Exploring NuCana plc ADR’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle
Analyzing NCNA’s price-to-book ratio for the last quarter - US Post News
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September - Benzinga
Endava PLC Sponsored ADR (DAVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Opera Limited Sponsored ADR (OPRA) Crossed Above the 20-Day Moving Average: What That Means for Investors - Yahoo Finance
Did Jim Cramer Say Buy Arm Holdings PLC – ADR (NASDAQ:ARM) Industrial Stock Before Rate Cuts? - Yahoo Finance
NuCana price target lowered to $25 from $150 at Oppenheimer - TipRanks
In the Green: NuCana plc ADR (NCNA) Closes at 3.66, Up/Down -52.65 from Previous Day - The Dwinnex
NuCana stock downgraded by William Blair after halted cancer study - Investing.com India
NuCana halts NuTide:323 study on colorectal cancer - Investing.com
NuCana Ends Phase 2 Cancer Study, Focuses on Promising Treatments - TipRanks
Check out these key findings about NuCana plc ADR (NCNA) - SETE News
NCNA’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.
NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update - The Bakersfield Californian
NuCana shares receive $150 stock PT at Oppenheimer on upbeat trial prospects - Investing.com
Sea Limited Sponsored ADR (SE) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
XPeng Inc. Sponsored ADR (XPEV) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Co-Diagnostics (CODX) to Post Q2 Earnings: What's in Store? - Yahoo Canada Shine On
NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag - Yahoo Singapore News
NuCana Stops Patient Enrollment in Pancreatic Cancer Study - Yahoo Sport Australia
Citi Appointed as Successor Depositary Bank for Iberdrola, S.A.’s ADR Programme - Yahoo Finance
NuCana to Participate in the 2022 Jefferies Healthcare Conference - The Globe and Mail
NuCana to Present at the Jefferies Virtual London Healthcare Conference - The Globe and Mail
Blueprint Medicines Files NDA to FDA for Pralsetinib in MTC - Yahoo Lifestyle UK
NuCana to Present at the Jefferies Global Healthcare Conference - GlobeNewswire Inc.
Blueprint Medicines Files NDA to FDA for Pralsetinib in MTC - Yahoo Singapore News
NuCana to Present at TD Cowen’s 5th Annual Oncology Innovation Summit - GlobeNewswire Inc.
NuCana Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.
Protagonist Therapeutics' PTG-300 Gets FDA's Orphan Drug Tag - Yahoo New Zealand News
Analysts Estimate Endava PLC Sponsored ADR (DAVA) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
NuCana (NCNA) Looks Good: Stock Adds 5.7% in Session - Yahoo New Zealand News
Bears are Losing Control Over NuCana PLC Sponsored ADR (NCNA), Here's Why It's a 'Buy' Now - Yahoo Lifestyle UK
Should You Buy NuCana (NCNA) Ahead of Earnings? - Yahoo News UK
NuCana (NCNA) to Report Q4 Earnings: What's in the Cards? - Yahoo Movies Canada
Should You Buy ARM Holdings (ARM) Ahead of Earnings? - Yahoo Finance
NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire Inc.
NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study - GlobeNewswire Inc.
NuCana plc Announces Reverse ADS Split - TipRanks
Nucana Plc Adr Stock (NCNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):